Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Novel transcript, antisense to PAK1 (ENSG00000268635) is a long noncoding RNA classified as a natural antisense transcript (NAT) that overlaps the PAK1 gene. NATs are widespread regulators in the genome, frequently exerting transcriptional and post-transcriptional control over their sense gene counterparts. Mechanisms include transcriptional interference (hindering sense gene expression by promoter competition or RNA polymerase collision), RNA masking (duplex formation that regulates splicing, stability, or translation), activation of RNA interference pathways (via double-stranded RNA formation), and epigenetic modification (such as inducing histone or DNA methylation). While antisense regulation of protein-coding genes like PAK1 can contribute to various biological outcomes—including cell proliferation, apoptosis, and gene silencing—the specific function and disease association for ENSG00000268635 remain uncharacterized in the literature. It is not regarded as a druggable molecular target, nor are there known drugs, biomarkers, or safety issues documented for this RNA gene[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to PAK1 (ENSG00000268635).